Key Findings - Design: Prospective, single-arm, open-label study - Participants: 16 adults with obesity and type 2 diabetes - Intervention: Tirzepatide 2.5 mg (4 weeks) 5 mg (8 weeks) Metabolic Improvements - Glucose infusion rate (GIR) from 3.21 to 5.16 mg/min/kg - HbA1c from 7.95% to 6.14% - Body weight by 4.9 kg (5%) - Fat mass by 9.1%, muscle mass by 1.8% - Glucagon from 28.8 to 20.8 pg/ml No Correlation Found - GIR changes werent significantly linked to other clinical variables Your Voice Matters: As GLP-1/GIP therapies evolve, should early improvements in insulin sensitivity influence how we define treatment success beyond weight loss and HbA1c
The recently described clinical spectrum for FAD synthase deficiency has ranged from neonatal-onset, a lethal disease with metabolic myopathy, cardiomyopathy, swallowing, speech difficulties, and respiratory insufficiency, to later-onset, a potentially treatable neuromuscular disorder with lipid storage myopathy, MADD-like metabolic aberrations, and combined respiratory-chain deficiency [34]
This gap between marketing and evidence is critical to understand before committing to online purchases
It is possible for patients to undergo swelling, bruising, or redness following treatment, but most will return to normal activities shortly afterward
